FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. 

Pharmaceutical

Biotechnology

FogPharma

Amanda Garofalo

John Doherty

Thomas Kotarako

Mathai Mammen

Dave Varon

Sandra Smith

Keith Orford

John Mcgee

Ashley Kancler

Kristen Stants

Research and Development Scientists

Leadership Team

Clinical and Translational Operations

Finance and Accounting

Teams at FogPharma

Research and Development Scientists

Leadership Team

Clinical and Translational Operations

Finance and Accounting